RussianPatents.com

Method of treating patients with chronic liver diseases in stage of latency and degree i manifested stage of hepatic encephalopathy. RU patent 2462251.

FIELD: medicine.

SUBSTANCE: invention refers to medicine and aims at treating the patients with chronic liver diseases (CLD) in the stage of latency and degree I manifested stage of hepatic encephalopathy. The preparation Essentiale forte N is used. It is combined with prescribing the preparation Mucofalk. The course is 28-30 days.

EFFECT: method enables reducing dyspepsia events and encephalopathy manifestations.

5 ex, 3 tbl, 1 dwg

IPC classes for russian patent Method of treating patients with chronic liver diseases in stage of latency and degree i manifested stage of hepatic encephalopathy. RU patent 2462251. (RU 2462251):

A61P1/16 - for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

A61K36/68 - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L)

A61K31/685 -

Another patents in same IPC classes:

Method of treating chronic viral hepatitis c / 2459629
Invention refers to medicine, namely hepatology and may be applicable in treating chronic viral hepatitis C. That is ensured by introducing short-lived interferon-alpha (IFN) and the nucleoside analogue Ribamidil in the patient with an initial average week dosage specified in the range of 10.5 to 21.0 mil. IU depending on the level of native patient's interferon-alpha. Interferon-alpha is introduced with at least twice gradually increase of the average week dose to 21.0 to 84 mil. IU. Over the whole period of introducing IFN, the patient is prescribed with additional antiviral preparations - an interferon inducer, as well as an amantadin preparation or a glycyrrhizic acid preparation. It is combined with a support therapy involving the introduction of T-cell immunity stimulators and preparations for correction of side effects. The presence of blood viral ribonucleic acid is occasionally controlled and the introduction of Ribamidil is started in a daily dose of 800-1200 mg from the third month from the beginning of treatment if observing the presence of ribonucleic acid or from the tenth month if observing the absence. The treatment is continued until at least a 12-month aviremia period is achieved.

Method of prevention and treatment of liver disease with application of receptor a<sub>2b</sub> antagonists

Method of prevention and treatment of liver disease with application of receptor a_2b antagonists / 2457842
Group of inventions relates to field of medicine. Method of treatment and prevention of liver fibrosis includes peroral introduction to mammal of therapeutically efficient amount of antagonist of adenosine receptor A2B - 3-ethyl-1-propyl-8-(1-{[3-(trifluormethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione. Method of reducing hepatotoxic side effects of chemical therapy or radiotherapy includes peroral introduction to mammal who underwent such treatment of therapeutically efficient amount of antagonist of adenosine receptor A2B - 3-ethyl-1-propyl-8-(1-{[3-(trifluormethyl)phenyl]methyl}pyrazol-4-yl) -1,3,7-trihydropurine-2,6-dione.

Granule and method for making thereof / 2456980
Invention refers to pharmaceutics. A pharmaceutical granule is spherical or spheroidal and has volume density 0.6-1.3 g/ml and disintegration 0.5-5 minutes. Active pharmaceutical ingredients are preparations of Traditional Chinese Medicine, herbal preparations or their extracts with a nucleus made of an extract of Traditional Chinese Medicine or herbal preparations, and a pharmaceutically acceptable carrier. The content of the pharmaceutically acceptable carrier with respect to total granule weight makes 10-60 wt %. The granule diameter can be equal to 700-1500 mcm. The granule nucleus diameter can be equal to 200-750 mcm. The granule can be also coated with a layer of 2-5 wt % with respect of total granule weight. A method for making the granules consists in introducing initial granules into a layer of a fluidised material as an excipient; the active pharmaceutical ingredients are prepared in the form of a suspension or a solution of the viscosity controlled within 6.0-9.8 MPa·s with using a viscosity-control agent; then they are sprayed over a surface of the initial granule for making a finished granule.

Method for preventing and treating hepatic consequences of ischemia / 2456678
Liver is resected in an animal experimentally. A pharmacological protection is presented by Mexicor and Serotonine Adipinate. On the operation day, 5% Mexicor is used in the form of intravenous slow stream introductions twice - 35 minutes before the operation in a dose of 5 mg/kg of weight and 11 hours after the first introduction in a dose of 7 mg/kg of weight. Serotonine Adipinate dissolved in 5 ml of isotonic solution NaCl is used in the form of intravenous slow stream introductions three times - 1 hour before the operation in a dose of 0.15 mg/kg of weight, 2 hours after the first introduction in a dose of 0.2 mg/kg of weight, 10 hours after the first introduction in a dose of 0.1 mg/kg of weight. During the postoperative period, Mexicor and Serotonine Adipinate are introduced for 8 days. Mexicor is introduced three times a day at 9 o'clock in a dose of 2.5 mg/kg of weight, at 15 o'clock in a dose of 1.5 mg/kg of weight, at 21 o'clock in a dose of 6 mg/kg of weight. Serotonine Adipinate is introduced twice a day - at 8 o'clock in a dose of 0.15 mg/kg of weight, at 17 o'clock in a dose of 0.1 mg/kg of weight.

Benzimidazole derivatives, based pharmaceutical composition and methods of using them / 2456276
Present invention refers to new benzimidazole derivatives of general formula (I) or to its pharmacologically acceptable salts wherein R1 represents a C6-aryl group which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), or a heterocyclic group which represents pyridyl, dihydrobenzofuranyl, 1,3-benzodioxolyl, tetrahydropyranyl, tetrahydrofuranyl which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), R2 represents a C1-C6 alkyl group, R3 represents a C6-aryl group which can be substituted by 1-2 groups optionally specified in a group of substitutes (a), Q represents a group represented by formula =CH-, or a nitrogen atom and a group of substitutes (a) represents a group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a carboxyl group, a C2-C7 alkylcarbonyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, an amino group, a 4-morpholinyl group and a di-C1-C6 alkyl)amino group. Also, the invention refers to a pharmaceutical composition based on a compound of formula (I), to a PPARγ activator/modulator based on the compound of formula (I), to using the compound of formula (I), to a method of reducing blood glucose, to a method of activating PPARγ, a method of treating and/or preventing said pathological conditions.

Method of preventing liver injury in formation of syndrome of combined dystrophic-degenerative changes of mesenchimal derivatives in case of local chronic inflammatory process and means for its realisation / 2455988
Claimed is means for prevention (prophylaxis) of liver injury in formation of syndrome of combined dystrophic-degenerative changes of mesenchimal derivatives in case of local chronic inflammatory process, located outside the liver (CDDCMD in case of LCIP located outside the liver), which represents hormone of pineal gland - melatonin and corresponding method of prevention (prophylaxis) of liver injury in formation of CDDCMD in case of LCIP.

Method of treating dyskinesia of gallbladder at background of chronic psycho-emotional stress / 2455970
Invention relates to medicine, namely to physiotherapy, gastroenterology. Method includes introduction of diet No5, internal intake of mineral water with the following carrying out transverse galvanisation of epigastrium area, general coniferous baths and impact with physical factor. As physical factor used is electromagnetic radiation of extremely high frequency (EHF). Impact is performed by broad-band noise emitter with frequency 40-63 GHz. Impact is performed on 3 and 4 projection zones in area of the right hypochondrium and on the area of sternum. Impact is performed daily, 10 minutes on each zone. Course includes 10-12 procedures.

Method for stimulating liver regeneration in fibrotic changes in experiment / 2455701
Under the conditions of modelling cirrhosis in experiment, the preparation EMBRYOBLASTE is introduced in liver tissue by means of an injector needle at the depth up to 0.1 cm. The preparation is introduced along a front surface of the liver, 2 injections in each lobe of the liver to form a papula. The volume of one injection makes 0.3 ml.

Use of xanthohumol and isoxanthohumol as active substance for preventing and/or controlling liver diseases / 2454996
Group of inventions refers to medicine and aims at preventing and treating a liver diseases. What is used is xanthohumol of formula (I) or xanthohumol metabolite as an active substance for making a preparation for preventing and/or controlling the liver diseases caused by obesity and/or diabetes. The daily dose varies within 0.01 to 161 mg/kg of weight. The xanthohumol content in the composition makes 0.1 to 99 wt %.

New piperazine amide derivatives / 2454412
Invention refers to new piperazine amide derivatives of formula wherein X represents N or CH; Y represents N or CH; R1 represents lower alkyl, phenyl, phenyl-lower alkyl wherein phenyl can be optionally substituted by 1-2 substitutes independently specified in a group consisting of halogen, lower alkyl; R2 represents lower alkyl, phenyl, naphthyl or heteroaryl specified in dimethylisoxazolyl, quinolinyl, thiophenyl or pyridinyl wherein phenyl or heteroaryl are optionally substituted by 1 substitute optionally specified in a group consisting of halogen, lower alkoxy group, fluor-lower alkyl, lower alkoxy-carbonyl and phenyl; R3 represents phenyl, pyridinyl or pyrazinyl wherein phenyl, pyridinyl or pyrazinyl are substituted by 1-2 substituted optionally specified in a group consisting of halogen, lower alkyl and fluor-lower alkyl; R4, R5, R6, R7, R8, R9, R10 and R11 independently represent hydrogen, as well as to their physiologically acceptable salts. These compounds are bound with LXR alpha and LXR beta, and are applicable as therapeutic agents for treatment and/or prevention of high lipid levels, high cholesterol levels, low HDL cholesterol, high LDL cholesterol, atherosclerotic diseases, diabetes, non insulin dependent diabetes mellitus, metabolic syndrome, dislipidemia, sepsis, inflammatory diseases, infectious diseases, skin diseases, colitis, pancreatitis, cholestasis, liver fibrosis, psoriasis, Alzheimer's disease, etc.

Therapeutic and prophylactic toothpaste / 2462231
Invention relates to creation of toothpaste for treatment of diseases of oral cavity mucosa and inflammatory diseases of periodontium tissues. Therapeutic and prophylactic toothpaste for treatment of inflammatory diseases of periodontium and oral cavity mucosa contains peptides associated with phospholipids, obtained from liver of Gadidae family with quantitative ratio, wt %: peptides 40-99 and phospholipids 1-60, as well as abrasive material, shape-forming thickening agent, water-retaining substance, cleaning and foam-generating component, preservative, dye, flavour and purified water in specified component ratio. Therapeutic and prophylactic toothpaste can additionally contain antioxidant, sweetener, plant extract, fluorides and/or desensitising agent. Application of toothpaste in short terms results in considerable improvement of state of periodontium and oral cavity tissues. In particular, fast elimination of inflammatory process, reduction of bleeding and painfulness of gums are observed.

Two-component composition for hair dyeing / 2462230
Invention relates to cosmetic industry and represents product for hair dyeing, which includes first component, including alkaline agent, second component, including hydrogen peroxide and foam-generating container of non-aerosol type for releasing solution of first and second component mixture in form of foam, where mixture solution includes the following ingredients (A) and (B): (A) from 0.1 to 10% by mass of non-ionic surface-active substance and (B) from 0.1 to 5% by mass of cation surface-active substance and mass ratio of ingredient (A) to ingredient (B) (content of ingredient (A)/content of ingredient (B) constitutes from 1 to 100.

Coloured aromatising alkyldiphenylacrylate-free composition which contains derivative of camphor benzylidene with sulfonic acid group or benzotriasol silicone / 2462229
Invention relates to coloured aromatizing composition, containing in cosmetically acceptable medium: a) at least 2 wt % of aromatising substance from total composition weight; b) at least one derivative of benzotriazole silicone of formula (1), c) at least one coloring agent, soluble in said medium, said composition does not contain compound β,β'-alkyldiphenylacrylate or α-cyano-β,β'-alkyldiphenylacrylate.

Changing hair colour with skin protection / 2462228
Invention relates to cosmetic field and deals with preparation for changing hair colour, which contains in cosmetic carrier at least one colour-changing component and combination (i) of not less than one corresponding to formula compound in amount from 0.01 to 7 wt % in terms of ready for application preparation, where R1, R2 and R3 are independently on each other represent atom of hydrogen, groups -CH3, -CH2CH3, -CH(CH3)2, -CH2CH2CH3, -CH(CH3)CH2CH3, -CH2CH(CH3)2, -C(CH3)3, n stands for 1 or 2; and (ii) of α-lipoic acid, in amount from 0.01 to 3.0 wt % calculated per weight of ready for application preparation. Invention also relates to method of changing hair colour with application of claimed preparation and application of said combination for changing hair colour which spares head skin.

Compositions of varnish for teeth including decoloured shellac and shellac wax used in dentistry and teeth care / 2462227
Group of inventions relates to field of medicine, namely to dentistry, and deal with varnish compositions for teeth and their application. Composition of teeth varnish includes active component and component which forms adhesive film, including decoloured shellac and shellac wax, shellac wax constituting from approximately 0.5 wt % to approximately 15 wt % of composition weight. Source of fluoride ion, antibacterial preparation, preparation reducing teeth sensitivity, preparation for teeth whitening or their combinations can be used and active component. Also claimed is application of claimed composition as means contributing to prevention and/or treatment of carious teeth decay, remineralisation of tooth surface and in case of teeth hypersensitivity. Inclusion of shellac wax in said amounts ensures improved varnish stability at higher temperature.

Method for correction of disturbed structural-functional properties of red cells and immune status in patients suffering acute pancreatitis / 2458688
Invention refers to medicine, namely surgery, and concerns correction of disturbed structural-functional properties of red cells and immune status in patients with acute pancreatitis. For this purpose a complex pharmacotherapy is added by the single intramuscular introduction of the preparation Longidase 3000 IU on the 3, 6, 9, 12 and 15 days; the intravenous drop infusion of the preparation hypoxene 2.0 g once a day for 7 days, by dissolving the content of ampoule ex tempore in 5% glucose 400 ml, and the intravenous slow introduction of Essentiale H 5.0 ml once a day for 10 days.